Sign in

Marc Stapley

Chief Executive Officer at VERACYTE
Board
Since June 1, 2021
Age
54 years
Education
Holds a B.Sc. (Honors) in Mathematics from The University of Reading (England).
Tenure
Joined VCYT as Chief Executive Officer on June 1, 2021 and as a board member on June 8, 2021.

Also at VERACYTE

AM
Annie McGuire
General Counsel and Chief People Officer
JL
John Leite
Chief Commercial Officer, CLIA
PF
Phillip Febbo
Chief Scientific Officer and Chief Medical Officer

About

Marc Stapley holds a B.Sc. (Honors) in Mathematics from The University of Reading (England), highlighting his strong academic background.

He has built a notable career in life sciences and healthcare, holding leadership roles at major companies such as Pfizer, Illumina, and Helix OpCo, LLC, which underscores his expertise in finance and executive management.

At VCYT, he joined as Chief Executive Officer on June 1, 2021 and became a member of the Board of Directors on June 8, 2021, reflecting his pivotal role in the company’s strategic direction.

His extensive experience in both operational and financial leadership, combined with his governance roles at other industry companies, provides a well-rounded foundation for his ongoing contributions at VCYT.

$VCYT Performance Under Marc Stapley

Past Roles

OrganizationRoleDate RangeDetails
Helix OpCo, LLC Chief Executive Officer April 2019 - May 2021 Served as CEO before joining VCYT
Illumina, Inc. Chief Financial Officer January 2012 - January 2017
Illumina, Inc. Chief Administrative Officer December 2015 - October 2017
Illumina, Inc. Executive Vice President October 2017 - January 2019
Pfizer Inc. Senior Vice President, Finance 2009 - 2012

External Roles

OrganizationRoleDate RangeDetails
Glaukos Corporation Board Member Since 2014 Active board membership
Helix Board Member Since 2015 Active board membership

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Salary$650,000 AnnuallyFixed annual base salary
Restricted Stock Units78,044 RSUs; $1,851,984 Fair Value Vesting: 1/4 on 1-year anniversary, then 1/16th quarterlyVesting acceleration upon specified events
Option Awards128,869 options; $1,927,416 Fair Value; $23.73/share Vesting: 1/4 on 1-year anniversary, then 1/48th monthlySubject to acceleration upon certain events
All Other Compensation$3,000 AnnuallyAdditional cash component

Performance Compensation

Data from  FY 2023

Annual Cash Incentive Plan

MetricWeightingThresholdTargetMaximumActualAchievement
Total Revenue60% $325M $340M $370M $358.5M 131% of target payout
Ending Cash Balance40% $150M $160M $200M $216.4M 150% of target payout
  • Corporate Multiplier: 138.5%
  • Target Bonus: $650,000
  • Earned Bonus: $900,250

Performance Stock Units (PSUs)

MetricValue
Grant DateMarch 6, 2023
Grant Date Fair Value$1,851,984
Grant Date Stock Price$23.73 per share
Threshold58,533 shares
Target78,044 shares
Maximum117,066 shares
Vesting Schedule40% vests in 2025 (performance period ending Dec 31, 2024) and 60% vests in 2026 (performance period ending Dec 31, 2025)
Vesting Range75% to 150% based on achievement of performance metrics
Max Outcome Value$3,220,486 if performance reaches 150% target
  • Conditions: Continued service and achievement of performance metrics are required; vesting may accelerate upon specified events